These results highlight ACLY as a potential dual-action therapeutic target in NAFLD and T2DM, and establish HP 13C MRS as a powerful translational tool for evaluating dynamic hepatic metabolic flux and therapeutic responses in metabolic disease. This evidence concerns the gene ACLY and metabolic dysfunction-associated steatotic liver disease.